|

Monalizumab (anti-NKG2A monoclonal antibody) Clinical Trials

1 actively recruiting trial

Also known as: humZ270, mAb IPH2201

Pipeline

Phase 2: 1

Top Sponsors

  • Istituto Clinico Humanitas1

Indications

  • MPN (Myeloproliferative Neoplasms)1
  • MDS (Myelodysplastic Syndrome)1
  • Acute Myeloid Leukaemia1
  • Cancer1

Other1 trial

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.